Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
22 hedge funds and large institutions have $30.2M invested in Soleno Therapeutics in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
16% more funds holding
Funds holding: 19 → 22 (+3)
14% more capital invested
Capital invested by funds: $26.4M → $30.2M (+$3.74M)
26.02% less ownership
Funds ownership: 72.11% → 46.09% (-26%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$231K |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$126K |
| 3 |
Renaissance Technologies
New York
|
+$113K |
| 4 |
VF
Virtu Financial
New York
|
+$62.2K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$60.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$906K |
| 2 |
BC
Birchview Capital
Burlington,
Vermont
|
-$737K |
| 3 |
6CM
683 Capital Management
New York
|
-$487K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$9.67K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |
SLNO Hedge Fund Activity: Q1 2019 in Review
22 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2019, worth a combined $30.2M — up 14% from $26.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SLNO positions and 2 closed out — a net gain of 3 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Oracle Investment Management, adding an estimated $231K. The largest seller was Sabby Management, exiting entirely with an estimated $906K sold.
- 22 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2019, up from 19 in Q4 2018.
- Funds reported $30.2M of Soleno Therapeutics stock for Q1 2019, up 14% quarter-over-quarter.
- 5 funds opened new Soleno Therapeutics positions in Q1 2019 and 2 closed out, a net change of +3 holders.
- The largest Soleno Therapeutics buyer in Q1 2019 was Oracle Investment Management, an estimated $231K added.
- The largest Soleno Therapeutics seller in Q1 2019 was Sabby Management, an estimated $906K sold.
Based on aggregated 13F filings for Q1 2019.